Pharmaceutical Executive-09-01-2021

Click the title above for a link to open the Pharmaceutical Executive September 2021 issue in an interactive PDF format.

Scientific advances are benefiting cancer patients, but it will take a pandemic-like response to ensure patients everywhere have access.

Though M&A activity and equity market outputs have been mixed, and pandemic challenges linger on, the outlooks for pharma and biotech remain stable—driven by R&D gains, record IPO levels.

Commercializing an orphan drug can be challenging, however, using a framework and a checklist that incorporates the right elements can prove beneficial.

Challenge assumptions and reset expectations when it comes to pre-launch SG&A investment to increase the odds of commercial success.

New drug aims to turn obesity into treatable chronic condition.

Peanut allergies raise fears among parents, teachers, but treatment is now available.

Hopeful new standard of care for advanced prostate cancer capitalizing on momentum.

The aggressive strategy behind a small company’s quick ascent in migraine market.

Latest disease-modifying market entrant for SMA addresses administration, access gaps.

Teva CEO Kåre Schultz talks about his long industry experience tackling major strategic and operational challenges, and how he is progressing on his current mission to turn around Teva’s fortunes.

Vaccines spotlight recent resurgence of useful messaging tool.

Digital transformation in medical affairs made a sluggish start, but there is plenty to be optimistic about.

If not addressed, effects could impact innovation, diversity.

Treatment availability for rare disease patients under fire in Europe.

But accelerated approval program faces scrutiny.

Looking Back at 2007–2010.

Pharm Exec profiles five recent drug launches and announces winners of first annual APEX Awards.

With opportunity and risk lurking in equal measure, today’s key considerations for biopharma startups when building their leadership teams and product go-to-market strategies are outlined.